IPP Bureau
Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD
By IPP Bureau - September 27, 2024
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
By IPP Bureau - September 27, 2024
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Granules India launches 'Breast Health Express' mobile unit
By IPP Bureau - September 26, 2024
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
Biocon Biologics Global to raise funds through senior secured notes
By IPP Bureau - September 26, 2024
The Notes shall not be offered or sold in India
Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as additional formulation in Japan
By IPP Bureau - September 26, 2024
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Pfizer withdraws all lots of sickle cell disease treatment voxelotor
By IPP Bureau - September 26, 2024
Pfizer's decision is based on the totality of clinical data
Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022
By IPP Bureau - September 25, 2024
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
Nadda asked NMC to add 75,000 medical seats
By IPP Bureau - September 25, 2024
NMC to continue its efforts to improve and enhance the quality of medical education in the country
Vaishali Pharma plans M&A route to drive growth
By IPP Bureau - September 25, 2024
Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies
Dr. Morepen’s diabetes awareness campaign kicks on KBC
By IPP Bureau - September 25, 2024
This initiative aims to raise awareness about the importance of monitoring blood sugar levels before indulging in sweets
Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024
By IPP Bureau - September 25, 2024
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
AstraZeneca Pharma India to launch Tremelimumab
By IPP Bureau - September 23, 2024
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
WHO endorses Roche’s dual-stain cytology testing in its cervical cancer prevention guidelines
By IPP Bureau - September 23, 2024
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results
DevCo completes strategic capital raise for investment in Medix Biochemica
By IPP Bureau - September 23, 2024
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
Sightsavers India and AbbVie India host consultation on Glaucoma prevention in Bhopal
By IPP Bureau - September 23, 2024
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
